Aardvark Therapeutics (AARD) Total Current Liabilities (2024 - 2026)
Aardvark Therapeutics (AARD) posted Total Current Liabilities of $11.6 million for Q1 2026, up 10.01% sequentially from $10.5 million in Q4 2025, and up 94.18% YoY from $6.0 million in Q1 2025.
Aardvark Therapeutics (AARD) Total Current Liabilities (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Total Current Liabilities for 3 years, with the latest figure at $11.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 94.18% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 94.18% YoY) and the FY2025 annual result came in at $10.5 million, up 114.09% from the prior year.
- Total Current Liabilities climbed to $11.6 million in Q1 2026 per AARD's latest filing, from $10.5 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $11.6 million in Q1 2026 and troughed at $4.9 million in Q4 2024.
- A 3-year average of $9.0 million and a median of $10.4 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Current Liabilities surged 114.09% in 2025, then soared 94.18% in 2026.
- Over 3 years, Total Current Liabilities stood at $4.9 million in 2024, then soared by 114.09% to $10.5 million in 2025, then grew by 10.01% to $11.6 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $11.6 million, $10.5 million, and $10.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.39 Mn |
| Mar 31, 2026 | 11.60 Mn |
| Dec 31, 2025 | 10.55 Mn |
| Sep 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 10.31 Mn |
| Mar 31, 2025 | 5.98 Mn |
| Dec 31, 2024 | 4.93 Mn |